A Randomized, Adaptive, Investigator/ Subject Blind, Single Ascending Dose, Placebo-Controlled Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered RO7049665 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2017
At a glance
- Drugs RG7835 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Roche
- 08 Nov 2017 Planned End Date changed from 31 Mar 2018 to 21 Feb 2018.
- 08 Nov 2017 Planned primary completion date changed from 31 Mar 2018 to 21 Feb 2018.
- 21 Jul 2017 New trial record